Immunological prevention of a multigene cancer syndrome

Stefania Croci, Giordano Nicoletti, Lorena Landuzzi, Caria De Giovanni, Annalisa Astolfi, Chiara Marini, Emma Di Carlo, Piero Musiani, Guido Forni, Patrizia Nanni, Pier Luigi Lollini

Research output: Contribution to journalArticle

Abstract

Vaccines effectively prevent the onset of tumors in transgenic mice carrying activated oncogenes; however, human tumors are caused by combined alterations in oncogenes and oncosuppressor genes. We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. A vaccine made of allogeneic mammary carcinoma cells expressing HER-2/neu and interleukin 12 afforded long-term protection from tumor onset. Tumor prevention was mediated by T cell-derived cytokines, in particular -y-interferon, and by anti-HER-2/neu antibodies. HER-2/neu expression was inhibited in target tissues of vaccinated mice, and somatic loss of the wild-type p53 allele did not occur. A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues.

Original languageEnglish
Pages (from-to)8428-8434
Number of pages7
JournalCancer Research
Volume64
Issue number22
DOIs
Publication statusPublished - Nov 15 2004

Fingerprint

Vaccines
Neoplasms
Oncogenes
Rhabdomyosarcoma
Oncogene Proteins
Human Mammary Glands
Interleukin-12
Salivary Glands
Interferons
Transgenic Mice
Carcinogenesis
Alleles
Breast Neoplasms
Cytokines
Carcinoma
T-Lymphocytes
Antibodies
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Croci, S., Nicoletti, G., Landuzzi, L., De Giovanni, C., Astolfi, A., Marini, C., ... Lollini, P. L. (2004). Immunological prevention of a multigene cancer syndrome. Cancer Research, 64(22), 8428-8434. https://doi.org/10.1158/0008-5472.CAN-04-2341

Immunological prevention of a multigene cancer syndrome. / Croci, Stefania; Nicoletti, Giordano; Landuzzi, Lorena; De Giovanni, Caria; Astolfi, Annalisa; Marini, Chiara; Di Carlo, Emma; Musiani, Piero; Forni, Guido; Nanni, Patrizia; Lollini, Pier Luigi.

In: Cancer Research, Vol. 64, No. 22, 15.11.2004, p. 8428-8434.

Research output: Contribution to journalArticle

Croci, S, Nicoletti, G, Landuzzi, L, De Giovanni, C, Astolfi, A, Marini, C, Di Carlo, E, Musiani, P, Forni, G, Nanni, P & Lollini, PL 2004, 'Immunological prevention of a multigene cancer syndrome', Cancer Research, vol. 64, no. 22, pp. 8428-8434. https://doi.org/10.1158/0008-5472.CAN-04-2341
Croci, Stefania ; Nicoletti, Giordano ; Landuzzi, Lorena ; De Giovanni, Caria ; Astolfi, Annalisa ; Marini, Chiara ; Di Carlo, Emma ; Musiani, Piero ; Forni, Guido ; Nanni, Patrizia ; Lollini, Pier Luigi. / Immunological prevention of a multigene cancer syndrome. In: Cancer Research. 2004 ; Vol. 64, No. 22. pp. 8428-8434.
@article{638c530fc2ea40af91f045b1392a1ed0,
title = "Immunological prevention of a multigene cancer syndrome",
abstract = "Vaccines effectively prevent the onset of tumors in transgenic mice carrying activated oncogenes; however, human tumors are caused by combined alterations in oncogenes and oncosuppressor genes. We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. A vaccine made of allogeneic mammary carcinoma cells expressing HER-2/neu and interleukin 12 afforded long-term protection from tumor onset. Tumor prevention was mediated by T cell-derived cytokines, in particular -y-interferon, and by anti-HER-2/neu antibodies. HER-2/neu expression was inhibited in target tissues of vaccinated mice, and somatic loss of the wild-type p53 allele did not occur. A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues.",
author = "Stefania Croci and Giordano Nicoletti and Lorena Landuzzi and {De Giovanni}, Caria and Annalisa Astolfi and Chiara Marini and {Di Carlo}, Emma and Piero Musiani and Guido Forni and Patrizia Nanni and Lollini, {Pier Luigi}",
year = "2004",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-04-2341",
language = "English",
volume = "64",
pages = "8428--8434",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Immunological prevention of a multigene cancer syndrome

AU - Croci, Stefania

AU - Nicoletti, Giordano

AU - Landuzzi, Lorena

AU - De Giovanni, Caria

AU - Astolfi, Annalisa

AU - Marini, Chiara

AU - Di Carlo, Emma

AU - Musiani, Piero

AU - Forni, Guido

AU - Nanni, Patrizia

AU - Lollini, Pier Luigi

PY - 2004/11/15

Y1 - 2004/11/15

N2 - Vaccines effectively prevent the onset of tumors in transgenic mice carrying activated oncogenes; however, human tumors are caused by combined alterations in oncogenes and oncosuppressor genes. We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. A vaccine made of allogeneic mammary carcinoma cells expressing HER-2/neu and interleukin 12 afforded long-term protection from tumor onset. Tumor prevention was mediated by T cell-derived cytokines, in particular -y-interferon, and by anti-HER-2/neu antibodies. HER-2/neu expression was inhibited in target tissues of vaccinated mice, and somatic loss of the wild-type p53 allele did not occur. A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues.

AB - Vaccines effectively prevent the onset of tumors in transgenic mice carrying activated oncogenes; however, human tumors are caused by combined alterations in oncogenes and oncosuppressor genes. We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. A vaccine made of allogeneic mammary carcinoma cells expressing HER-2/neu and interleukin 12 afforded long-term protection from tumor onset. Tumor prevention was mediated by T cell-derived cytokines, in particular -y-interferon, and by anti-HER-2/neu antibodies. HER-2/neu expression was inhibited in target tissues of vaccinated mice, and somatic loss of the wild-type p53 allele did not occur. A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues.

UR - http://www.scopus.com/inward/record.url?scp=8544275868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544275868&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-2341

DO - 10.1158/0008-5472.CAN-04-2341

M3 - Article

C2 - 15548714

AN - SCOPUS:8544275868

VL - 64

SP - 8428

EP - 8434

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 22

ER -